Tharimmune to Present at the Microcap Conference 2025
-
BRICS nations slam Trump tariffs, condemn strikes on Iran
-
MLB Nationals fire manager Martinez, GM Rizzo after loss
-
US tariffs to kick in Aug 1, barring trade deals
-
Trump slams former ally Musk's political party as 'ridiculous'
-
Three things we learned from the second England-India Test
-
Norway reach Euro 2025 quarter-finals as Swiss down eliminated Iceland
-
Alcaraz vows to avoid Murray after defeat on golf course
-
Alcaraz finds magic touch at Wimbledon as Sabalenka storms into quarter-finals
-
Run-hungry Gill glad to 'lead by example' as India level England series
-
Rockets confirm arrival of Durant in unprecedented NBA seven-team trade
-
Alcaraz survives Rublev test to stay on course for Wimbledon hat-trick
-
New Zealand's Dixon wins seventh IndyCar Mid-Ohio title
-
US tariffs to kick in Aug 1, barring trade deals: Bessent
-
England consider Archer and Atkinson recall after heavy India defeat
-
Durant deal becomes NBA-record seven-team trade: reports
-
Verstappen laments 'really difficult' Silverstone fifth
-
BRICS nations hit out at Trump tariffs
-
Hansen shoots Norway to brink of Euro 2025 quarter-finals
-
Jennifer Geerlings-Simons becomes Suriname's first woman president
-
Netanyahu says Trump meeting could 'advance' Gaza deal ahead of Doha talks
-
BRICS meeting in Rio hits out at Trump tariffs
-
Hulkenberg shakes off F1's longest unwanted record with podium finish at Silverstone
-
US tariffs to kick in Aug 1 barring trade deals: Treasury Secretary
-
Norris in dream land after epic home win at Silverstone
-
Sabalenka storms into Wimbledon quarters as Alcaraz braces for Rublev test
-
Sabalenka downs former doubles partner to power into Wimbledon quarters
-
'Jurassic World: Rebirth' roars to top of N.American box office
-
Wimbledon's underdogs enjoy their week in the sun
-
Deep strikes as India hammer England in second Test
-
Sabalenka powers into Wimbledon quarter-finals
-
Dutch powerhouse Van der Poel takes Tour de France lead
-
Emotional Norris wins epic rain-hit British Grand Prix
-
Australian pacemen rattle West Indies run chase
-
Syria fights 'catastrophic' fires for fourth day
-
'Stole the game': Wimbledon line-calling tech malfunctions
-
Van der Poel powers into Tour de France lead
-
Norris wins home British Grand Prix
-
Wimbledon line-calling tech malfunctions
-
BRICS gather in Rio as Trump tariff wars loom
-
Bayern's Musiala out for 'long period' with broken fibula
-
Deep leaves England on brink of defeat as India eye series-levelling win
-
Caldentey's Arsenal stint boosting her bid for Euros and Ballon d'Or glory
-
Fritz into Wimbledon quarter-finals after Thompson retires
-
Armed gang attacks Kenya Human Rights Commission on eve of protests
-
Hezbollah chief says won't surrender under Israeli threats
-
Arsenal sign Spain midfielder Zubimendi
-
India resume quest to level England series after rain delay
-
Arsenal sign midfielder Zubimendi from Real Sociedad
-
Alcaraz seeks top gear at Wimbledon as Sabalenka stays calm
-
'Emergency' at Afghan border as migrant returns from Iran surge ahead of deadline
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
